Navigation Links
WuXi PharmaTech Appoints Ying Han to Its Board of Directors
Date:11/12/2008

SHANGHAI, China, Nov. 12 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has appointed Ms. Ying Han to its Board of Directors.

From 1998 to 2006, Ms. Han worked for NASDAQ-listed Asiainfo as Chief Financial Officer and Executive Vice President. Earlier she spent 10 years in Hewlett Packard (China), serving in various functions until assuming the responsibility of Chief Controller and Business Development Director. Ms. Han is currently an advisor to Warburg Pincus, a leading global private equity firm.

"We are very pleased to welcome Ying on board to further enhance the supervision and conduct of our overall business and financial affairs," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Ying's addition to our board with her invaluable finance and business experience will help WuXi better manage its business and financial system and ultimately increase the overall value of WuXi."

Ms. Han received a college degree in Western Accounting from Xiamen University, China.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

For more information, please contact:

Sherry Shao

WuXi PharmaTech (Cayman) Inc.

Tel: +86-21-5046-4002

Email: pr@wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Announces Third Quarter 2008 Results
2. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
3. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
4. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
5. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
6. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
7. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
8. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
9. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
10. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
11. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... T3D Therapeutics, ... new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. Kathleen ... we seek to uniquely treat the metabolic dysfunctions inherent in Alzheimer’s disease and ...
(Date:3/27/2017)... March 27, 2017 Roka Bioscience, Inc. (NASDAQ: ROKA), ... for the detection of foodborne pathogens,  today announced that ... Company Spring 2017 Convention on March 29 at 9:50am ET. ... Marquis. About Roka Bioscience ... Roka Bioscience is ...
(Date:3/27/2017)... ATLANTA , March 27, 2017 Cousins Properties ... of the world,s leading biotechnology companies, has signed a 10-year, ... foot Class A office asset located in the Westshore submarket ... "We are thrilled that Amgen has chosen Corporate Center for ... Larry Gellerstedt , president and chief executive officer of ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), ... the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is ... ) and the US National Institutes of Health. ... ... ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant ... At PTE ... March, Materna will present its complete end-to-end passenger journey, ... real benefit for passengers. To accelerate the whole passenger handling ... solutions to take passengers through the complete integrated process with ...
Breaking Biology News(10 mins):